Why Every Conglomerate on Earth Is Chasing Your Skin

Industry Autopsy #006

Three of the world’s largest companies restructured around the same category this week, and it had nothing to do with selling you a better moisturizer.

Unilever reportedly began exploring the separation of its entire €30 billion food business. The reason is straightforward — beauty and personal care generated €26 billion in 2025 revenue, more than double what food produced, with significantly higher margins and stronger long-term growth. Bloomberg reported that CEO Hein Schumacher is evaluating a full split to double down on the category that’s actually driving the company forward.

At the same time, L’Oréal — the world’s largest beauty company — continued building out what is quietly becoming the most ambitious longevity infrastructure in the industry. A joint longevity venture with Kering (the group behind Gucci and Saint Laurent). A 20% acquisition of Galderma. An NVIDIA-powered AI system analyzing over 260 skin biomarkers, unveiled at CES 2026, that predicts molecular behavior at the atomic level. And its own brand Lancôme launched a longevity cream powered by biotech startup Timeline’s Mitopure.

Symrise, one of the world’s largest fragrance and ingredient suppliers — the company behind the formulas that major beauty brands put their names on — restructured its entire Scent & Care segment into a new longevity-focused Care & Wellness division.

And Estée Lauder Companies, the conglomerate behind Clinique, La Mer, Origins, and dozens of other brands, presented sirtuin and exosome longevity research at IMCAS 2026.

Why skin, and why now?

These moves only make sense when you understand what skin actually is from a biological standpoint. It’s the only organ that can be photographed, measured non-invasively, and tracked at consumer scale. And a growing body of research links skin biomarkers — collagen density, epidermal thickness, melanin distribution, wrinkle depth progression — to biological age broadly.

That makes skin the interface between cosmetics and longevity medicine, between consumer products and biological data. The conglomerates aren’t just chasing beauty margins. They’re positioning themselves at the intersection of a consumer category they already dominate and a longevity science market that’s attracting billions in investment from companies like Altos Labs, Retro Biosciences, and NewLimit.

When L’Oréal says “longevity science in beauty” at CES, they mean it literally.

What this changes for consumers

When the biggest companies on earth start treating your skin as a biological data source rather than a surface to moisturize, the bar for what counts as effective skincare shifts permanently. Clinical backing and disclosed concentrations are moving from differentiators to baseline expectations. Products that can’t meet that standard become harder to justify, regardless of how much marketing is behind them.

What this changes for brands

Self-reported clinical claims aren’t going to hold up in a world where conglomerates are building biomarker-level evaluation infrastructure. Brands that want to compete in the era of longevity science need their clinical data independently validated — not just published on their own product page, but evaluated against a standard that consumers and retailers can actually trust.

That’s what the Protocol was built for. It’s the only publicly documented clinical evaluation standard in beauty, and the brands that pass it are the ones built for where this industry is going.

If your formulations have the science to back them up, apply for evaluation -> utopiabeauty.co/b2b-landing

-----

*Industry Autopsy is a recurring series from Utopia Beauty that uses financial data, clinical evidence, and market analysis to cut open what’s actually happening in the beauty industry. Follow along on [Instagram](https://instagram.com/shoputopiabeauty).*